Cancer Family
Central Nervous System Neoplasm
CI-CAN-00000118Explore in graph →
Non-malignant1,345 active trials7 approved drugs177 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000118Explore in graph →
Clinical trials
5,060 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00704288 | Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme | completed | Phase 2 | 222 | ExelixisINDUSTRY | 1 | Feb 5, 2024 | clinicaltrials |
| NCT02206230 | Trial of Hypofractionated Radiation Therapy for Glioblastoma | completed | Phase 2 | 133 | AHS Cancer Control AlbertaOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02842723 |
| Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma) |
| completed |
| Phase 2 |
| 33 |
| Institut CurieOTHER |
| 1 |
| Jan 31, 2024 |
| clinicaltrials |
| NCT01811498 | Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM | completed | Phase 1 / Phase 2 | 31 | Northwell HealthOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT02073968 | PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer(PAINT) | completed | Phase 2 | 35 | Albert Einstein College of MedicineOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT01854554 | Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT) | completed | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | completed | Phase 2 | 151 | Novartis PharmaceuticalsINDUSTRY | 20 | Dec 13, 2023 | clinicaltrials |
| NCT02839720 | Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 6, 2023 | clinicaltrials |
| NCT01128218 | A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors | completed | Phase 1 / Phase 2 | 33 | Southern Illinois UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03255018 | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03027388 | Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | completed | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02315534 | A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma | completed | Phase 1 / Phase 2 | 34 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Nov 15, 2023 | clinicaltrials |
| NCT00588523 | Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma | completed | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT03158389 | NCT Neuro Master Match - N²M² (NOA-20)(N²M²) | completed | Phase 1 / Phase 2 | 228 | University Hospital HeidelbergOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT04119674 | Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 33 | Zhejiang Cancer HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT01508221 | Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis | completed | Phase 2 | 31 | University of CincinnatiOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT01259869 | A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression | completed | Phase 2 | 34 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 22, 2023 | clinicaltrials |
| NCT03520842 | Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02330991 | A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse | completed | Phase 2 | 204 | Beijing Sanbo Brain HospitalOTHER | 0 | Jul 24, 2023 | clinicaltrials |
| NCT04659421 | Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas | completed | Phase 2 | 60 | Beijing Sanbo Brain HospitalOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05096468 | Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms. | completed | Phase 2 / Phase 3 | 90 | Beijing Tiantan HospitalOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT01290692 | Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma | completed | Phase 2 | 14 | TVAX BiomedicalINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01466686 | Low Dose Radiation Therapy for Glioblastoma Multiforme | completed | Phase 2 | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01689727 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors | completed | Phase 2 | 40 | EndocyteINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02661282 | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | completed | Phase 1 / Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03032484 | TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma | completed | Phase 2 | 25 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT01188096 | A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas(Poly-ICLC) | completed | Phase 2 | 23 | Wake Forest University Health SciencesOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT02366728 | DC Migration Study for Newly-Diagnosed GBM(ELEVATE) | completed | Phase 2 | 64 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT00662506 | Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2023 | clinicaltrials |
| NCT01081223 | Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma | completed | Phase 1 / Phase 2 | 12 | TVAX BiomedicalINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT02879682 | nTMS for Motor Mapping of Rolandic Lesions(Motorstim) | completed | Phase 2 / Phase 3 | 330 | Technical University of MunichOTHER | 3 | Jun 1, 2023 | clinicaltrials |
| NCT00187226 | A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects | completed | Phase 2 | 361 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT02333565 | Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas(CEVOREM) | completed | Phase 2 | 20 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT04507217 | Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC | completed | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT03618667 | GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification | completed | Phase 2 | 13 | Samsung Medical CenterOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT03849105 | 131I-IPA and Concurrent XRT in Recurrent GBM(IPAX-1) | completed | Phase 1 / Phase 2 | 10 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 3 | Apr 14, 2023 | clinicaltrials |
| NCT01182415 | High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT00582075 | Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases(RAD0102) | completed | Phase 2 | 25 | University of Alabama at BirminghamOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT03242824 | The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma | completed | Phase 2 | 21 | Mayo ClinicOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT01792310 | A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours | completed | Phase 1 / Phase 2 | 54 | Laminar PharmaceuticalsINDUSTRY | 2 | Feb 21, 2023 | clinicaltrials |
| NCT00100802 | Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03273712 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | completed | Phase 2 | 39 | University of IowaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT04657315 | Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients(MSC11FCD-GBM) | completed | Phase 1 / Phase 2 | 10 | CHA UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02017964 | Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma | completed | Phase 2 | 26 | Children's Oncology GroupNETWORK | 4 | Jan 9, 2023 | clinicaltrials |
| NCT00312728 | A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) | completed | Phase 2 | 115 | Genentech, Inc.INDUSTRY | 0 | Jan 6, 2023 | clinicaltrials |
| NCT01730950 | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 182 | Radiation Therapy Oncology GroupNETWORK | 1 | Dec 29, 2022 | clinicaltrials |
| NCT04444427 | Evaluation of GLR2007 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 19 | Gan and Lee Pharmaceuticals, USAINDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT04934579 | Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma | completed | Phase 2 | 17 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 23, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 5, 2024source: clinicaltrials